Previous 10 | Next 10 |
Cranbury NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, congratulates Gregg L. Semenza, M.D., Ph.D., scientific advisory board member at Raf...
Rafael Holdings (NYSEMKT: RFL ): Q4 GAAP EPS of -$0.16. Revenue of $1.4M Press Release More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news,
NEWARK, N.J. , Oct. 3, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $4.9 million and a loss per share of $0.35 for the fiscal year ended July 31, 2019 . Fourth quarter revenue was $1.4 million and the loss per share was $0.16 . ...
Newark, NJ, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Wendy McDermott as Chief People Officer. McDermott...
CRANBURY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Phase 3 clinical trial ( ARMADA 2000 ) of CPI-613® ...
CRANBURY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 3 clinical trial for patients with met...
Cranbury, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that peer-reviewed medical journal Future Oncology published two m...
This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 08/05/2019. Please visit our Tracking Kahn Brothers Portfolio series t...
Jerusalem, Aug. 05, 2019 (GLOBE NEWSWIRE) -- LipoMedix Pharmaceuticals Ltd. , a clinical and development-stage company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery, today announced the addition of Miranda J. Toledan...
Newark, NJ, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the launch of Rafael Trial Connect , a web portal available on the...
News, Short Squeeze, Breakout and More Instantly...
Rafael Holdings Inc. Class B Company Name:
RFL Stock Symbol:
NYSE Market:
Rafael Holdings Inc. Class B Website:
NEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. “We remain committed to strategically and opportunistically deployi...
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet allows us to continue to fund our pipeline assets ...
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our real estate asset located in N...